Maryaline Catillon
Education
Ph.D., health policy, Harvard University; M.P.H., Pasteur Institute-CNAM School of Public Health; LL.M. and LL.B., Toulouse University; M.A., contemporary history and political science, Paris University; B.S., mathematics and physics, Paris University
Summary of Experience
Dr. Catillon specializes in health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include the design of real-world studies, chart reviews, surveys, discrete choice experiments; retrospective database analyses using medical claims, electronic health records, and clinical trial data; indirect treatment comparisons such as matching-adjusted indirect comparisons and network meta-analyses; and machine learning applications. Her work encompasses therapeutic fields such as oncology, infectious diseases, ophthalmology, and psychiatry. Dr. Catillon’s research has been presented at international conferences and published in peer-reviewed journals such as Health Economics, Leukemia & Lymphoma, and The Journal of Clinical Psychiatry. She has served as a peer reviewer for journals such as The BMJ, Health Services Research, and Management Science. She has taught at Harvard University and the NYU Grossman School of Medicine, and is affiliated with the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Dr. Catillon serves as an expert on the scientific advisory board of projects funded by Horizon Europe, the EU’s research and innovation program (REMEDIA). She is vice president of the Sergei S. Zlinkoff Fund for Medical Research and Education. Prior to joining Analysis Group, Dr. Catillon was the CFO of a hospital in France.
-
Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study
Leukemia & Lymphoma, 2024
2024Huntington SF, Cheng WY, Sarpong EM, Leng S, Farooqui MZH, Agu US, Catillon M, Lejeune D, Downes N, Matay L, Duh MS, Nigris ED
-
Assessment of centanafadine in adults with ADHD: a matching adjusted indirect comparison versus methylphenidate hydrochloride extended release (Concerta)
Current Medical Research and Opinion, 2024
2024Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Qu A, Childress A
-
Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release
Journal of Managed Care & Specialty Pharmacy, 2024
2024Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Chan D, Childress A
-
Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder - A Discrete Choice Experiment
Patient Preference and Adherence, 2024
2024Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Meng Y, Libchaber B, Jiang F, Childress A
-
A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy
Journal of Comparative Effectiveness Research, 2024
2024Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Qu A, Lee F, Childress A
-
Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study
Scientific Reports, 2023
2023Naber KG, Wagenlehner F, Kresken M, Cheng WY, Catillon M, Duh MS, Yu L, Khanal A, Mulgirigama A, Joshi AV, Ju S, Mitrani-Gold FS
-
The Economic Burden of Schizophrenia in the United States
Journal of Clinical Psychiatry, 2022
2022Kadakia A, Catillon M, Fan Q, Williams GR, Marden JR, Anderson A, Kirson N, Dembek C